Physician profile
Subhash P Sheth
NPI 1942201652
$1,423.88
in general payments reported to CMS, 2019-2025
24 companies · $268 in 2025
The $268 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $446 · 2021: $85.23 · 2022: $29.11 · 2023: $169 · 2024: $15.80 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $196.33 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $168.28 | 2019-2023 | |
| Abiomed | $145.77 | 2025 | |
| Merck Sharp & Dohme LLC | $132.58 | 2019-2021 | |
| Sirtex Medical INC | $128.01 | 2023 | Sir-Spheres Microspheres |
| Astrazeneca Pharmaceuticals Lp | $111.37 | 2019-2020 | |
| Amgen INC. | $72.70 | 2020-2022 | |
| Beigene USA, INC. | $57.15 | 2020-2021 | |
| Pfizer INC. | $51.23 | 2019-2020 | |
| Gilead Sciences, INC. | $48.37 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $37.65 | 2019 | |
| Seagen INC. | $35.82 | 2020 | |
| Eisai INC. | $31.05 | 2019-2020 | |
| Array Biopharma INC | $28.45 | 2019-2020 | |
| Daiichi Sankyo INC. | $27.58 | 2021-2024 | Injectafer |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $27.18 | 2020 | |
| Kyowa Kirin, INC. | $25.06 | 2020 | |
| Celgene Corporation | $18.29 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $17.54 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.76 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.69 | 2019 | |
| Acceleron Pharma, INC. | $12.89 | 2020 | |
| Glaxosmithkline, LLC. | $12.01 | 2020 | |
| Lilly USA, LLC | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subhash Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.